Literature DB >> 12621636

Increased daytime sleepiness in Parkinson's disease: a questionnaire survey.

Birgit Högl1, Klaus Seppi, Elisabeth Brandauer, Susanne Glatzl, Birgit Frauscher, Ulrike Niedermüller, Gregor Wenning, Werner Poewe.   

Abstract

We evaluated the frequency and severity of excessive daytime sleepiness in an outpatient population with Parkinson's disease in comparison to age-matched controls and examined its relationship with antiparkinsonian drug therapy and sleep history. Increased daytime sleepiness and involuntary sleep episodes have been described in Parkinson's disease, but the etiology is not completely understood. The Epworth Sleepiness Scale (ESS), a validated questionnaire for daytime sleepiness, was prospectively administered to 99 consecutive outpatients with Parkinson's disease and 44 age-matched controls. In addition, a short sleep-screening questionnaire was used. The ESS revealed significantly increased daytime sleepiness in PD patients compared to controls (7.5 +/- 4.6 vs. 5.8 +/- 3.0, P = 0.013). The ESS score was abnormally high (10 or more) in 33 % of PD patients and 11.4% of controls (P = 0.001). ESS was not different between PD patients on levodopa monotherapy and those on levodopa and dopamine agonists, or between patients taking ergoline or non-ergoline dopamine agonists. In PD patients and in controls, sleepiness was significantly associated with reported heavy snoring. Increased daytime sleepiness is more frequent in patients with PD than in elderly controls. Similar to controls, increased daytime sleepiness in PD patients is correlated with heavy snoring. Copyright 2002 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12621636     DOI: 10.1002/mds.10365

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  9 in total

1.  Sleep disturbances in untreated Parkinson's disease.

Authors:  Jitka Bušková; Jiří Klempíř; Veronika Majerová; Jana Picmausová; Karel Sonka; Robert Jech; Jan Roth; Evžen Růžička
Journal:  J Neurol       Date:  2011-06-03       Impact factor: 4.849

2.  Parkinsonism with excessive daytime sleepiness--a narcolepsy-like disorder?

Authors:  Christian Baumann; Luigi Ferini-Strambi; Daniel Waldvogel; Esther Werth; Claudio Lino Bassetti
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

Review 3.  Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease.

Authors:  Lindy D Wood
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

Review 4.  Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.

Authors:  Cristina Politi; Cinzia Ciccacci; Giuseppe Novelli; Paola Borgiani
Journal:  Neuromolecular Med       Date:  2018-01-05       Impact factor: 3.843

5.  Comparative levels of excessive daytime sleepiness in common medical disorders.

Authors:  Alice F Stroe; Thomas Roth; Catherine Jefferson; David W Hudgel; Timothy Roehrs; Kenneth Moss; Christopher L Drake
Journal:  Sleep Med       Date:  2010-10       Impact factor: 3.492

6.  Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study.

Authors:  Tanya Simuni; Chelsea Caspell-Garcia; Christopher Coffey; Lama M Chahine; Shirley Lasch; Wolfgang H Oertel; Geert Mayer; Birgit Högl; Ron Postuma; Aleksandar Videnovic; Amy Willis Amara; Ken Marek
Journal:  Mov Disord       Date:  2015-06-11       Impact factor: 10.338

7.  Sleep disorders in Parkinson's disease.

Authors:  Cynthia L Comella
Journal:  Curr Treat Options Neurol       Date:  2008-05       Impact factor: 3.598

Review 8.  How to optimize the treatment of early stage Parkinson's disease.

Authors:  Fabrizio Stocchi; Laura Vacca; Fabiana G Radicati
Journal:  Transl Neurodegener       Date:  2015-02-25       Impact factor: 8.014

9.  Prevalence of sleep disorders in Parkinson's disease patients in two neurology referral hospitals in Ethiopia.

Authors:  Dereje Melka; Abenet Tafesse; James H Bower; Demeke Assefa
Journal:  BMC Neurol       Date:  2019-08-22       Impact factor: 2.474

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.